05 April 2021

Global pharmaceutical industry has become the field for serious patent-related battles between producers of original drugs and manufacturers of generics.

Particularly this trend is widely observed in the former USSR and Eastern Europe countries, where the regulatory bodies and courts have not yet developed an efficient mechanism for maintaining the balance of interests between the pharmaceutical businesses, state and patients.

Having vast expertise in providing legal protection to large Russian and international pharmaceuticals and healthcare companies in EAEU, CIS and Eastern Europe, Lidings publishes Legal Digest highlighting the most notable patents disputes in Life Sciences that have been recently taking place in those jurisdictions.

Lidings Recommended by World Trademark Review 1000

18 February 2021

The rating particularly states that Andrey is “well versed in all aspects of intellectual property and can hammer out favourable outcomes in difficult disputes in the life sciences, fast-moving consumer goods and high-technology spheres” and Boris is “a trusted adviser to numerous pharmaceutical companies on both the patent and trademark sides, and has further know-how in advertising and data protection.

The Russian Government has granted the first compulsory license “in the interests of public security”

03 February 2021

On January 5, 2021 the Decree of the Government of the Russian Federation No. 3718-r dated December 31, 2020 (the Decree) was published. In accordance with the Decree, Pharmasintez JSC, a Russian generic company, has been granted a 1-year compulsory license to use the inventions of the US companies Gilead Sciences Inc. and Gilead Pharmasset LLC protecting Remdesivir subject to a “fair compensation”1.